FrancophonIA/ELRC3.0 huggingface dataset:
English: In the event of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately.
Slovenian: V primeru prevelikega odmerjanja je priporočljivo bolnika nadzorovati za znake in simptome neželenih učinkov ter nemudoma uvesti ustrezno simptomatsko zdravljenje.
English: Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment (see section 5.2).
Slovenian: Bolniki, ki se zdravijo z risankizumabom, ne smejo prejeti živih cepiv med zdravljenjem in še vsaj 21 tednov po zdravljenju (glejte poglavje 5.2).
English: Anxiety and depression, as measured by the Hospital Anxiety and Depression Scale (HADS), improved in the risankizumab group at week 16 compared with the placebo group.
Slovenian: Anksioznost in depresija, merjeni z lestvico HADS (Hospital Anxiety and Depression Scale), sta se v skupini, ki je prejemala risankizumab, izboljšali v 16. tednu v primerjavi s placebo skupino.
English: Detailed and updated information on this product is available by scanning the QR code included below or on the outer carton with a smartphone.
Slovenian: Podrobne in posodobljene informacije o zdravilu so vam na voljo, če s pametnim telefonom skenirate QR-kodo, ki je spodaj in na zunanji ovojnini.
English: No dose adjustment based on body weight is currently recommended.
Slovenian: Prilagoditev odmerka glede na telesno maso trenutno ni priporočljiva.
English: The majority of cases were non-serious and mild to moderate in severity and did not lead to discontinuation of risankizumab.
Slovenian: Večina primerov ni bila resna, bili so blagi do zmerni in niso povzročili prenehanja uporabe risankizumaba.
English: If a dose is missed, the dose should be administered as soon as possible.
Slovenian: V primeru izpuščenega odmerka je treba odmerek uporabiti čim prej.
English: Prior to use, a visual inspection of each pre-filled syringe is recommended.
Slovenian: Pred uporabo je priporočljivo vsako napolnjeno injekcijsko brizgo pregledati.
English: If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.
Slovenian: Če ste noseči, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden uporabite to zdravilo.
English: Table 5: Efficacy results 28 weeks after re-randomisation in IMMVENT Switched to Risankizumab (N=53) n (%)
Slovenian: Preglednica 5: Rezultati učinkovitosti 28 tednov po ponovni randomizaciji v študiji IMMVENT Prehod na risankizumab (N = 53) n (%)
English: The European Medicines Agency has deferred the obligation to submit the results of studies with risankizumab in one or more subsets of the paediatric population in the treatment of plaque psoriasis (see section 4.2 for information on paediatric use).
Slovenian: Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z risankizumabom za eno ali več podskupin pediatrične populacije za zdravljenje psoriaze (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
English: Week 52 249 (81.9) PASI 100
Slovenian: 52. teden 249 (81,9) PASI 100
English: Across all studies, 30.9% of subjects were naïve to any systemic therapy (including non-biologic and biologic), 38.1% had received prior phototherapy or photochemotherapy, 48.3% had received prior non-biologic systemic therapy, 42.1% had received prior biologic therapy, and 23.7% had received at least one anti-TNF alpha agent for the treatment of psoriasis.
Slovenian: V vseh študijah skupaj je bilo 30,9 % bolnikov, ki dotlej niso prejemali nobene sistemske terapije (vključno z nebiološkimi in biološkimi zdravili), 38,1 % jih je bilo predhodno zdravljenih s fototerapijo ali fotokemoterapijo, 48,3 % jih je predhodno prejemalo nebiološka sistemska zdravila, 42,1 % jih je predhodno prejemalo biološka zdravila in 23,7 % jih je prejemalo vsaj eno zdravilo proti TNF- alfa za zdravljenje psoriaze.
English: Baseline sPGA score was severe in 19.3% of subjects and moderate in 80.7% of subjects.
Slovenian: Izhodiščna ocena sPGA je bila huda pri 19,3 % preiskovancev in zmerna pri 80,7 % preiskovancev.
English: Therapeutic IgG monoclonal antibodies are typically degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgGs.
Slovenian: Terapevtska monoklonska protitelesa IgG se tipično po kataboličnih poteh razgradijo v majhne peptide in aminokisline, enako kot endogeni IgG.
English: The efficacy and safety of risankizumab was assessed in 2,109 subjects with moderate to severe plaque psoriasis in four multicentre, randomised, double-blind studies (ULTIMMA-1, ULTIMMA-2, IMMHANCE, and IMMVENT).
Slovenian: Učinkovitost in varnost risankizumaba so ocenili pri 2109 preiskovancih z zmerno do hudo psoriazo v plakih v štirih multicentričnih, randomiziranih, dvojno slepih študijah (ULTIMMA-1, ULTIMMA-2, IMMHANCE in IMMVENT).
English: Adverse reactions for risankizumab from clinical studies (Table 1) are listed by MedDRA system organ class and are based on the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); and very rare (< 1/10,000).
Slovenian: Neželeni učinki risankizumaba iz kliničnih študij (preglednica 1) so našteti po organskem sistemu MedDRA in razvrščeni po naslednjem dogovoru: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) in zelo redki (< 1/10.000).
English: • Inject the second syringe straight after the first injection but at least 3 cm away from the first injection
Slovenian: • Z drugo brizgo injicirajte takoj za prvo, vendar vsaj 3 cm stran od prve injekcije.
English: Among the few subjects (approximately 1%; 7/1,000 at week 16 and 6/598 at week 52) with high antibody titers (>128), clinical response appeared to be reduced.
Slovenian: Med maloštevilnimi preiskovanci (približno 1 %; 7/1.000 v 16. tednu in 6/598 v 52. tednu) z visokimi titri protiteles (> 128) se je klinični odziv zmanjšal.
English: Percent of Subjects
Slovenian: Odstotek preiskovancev
English: It also reduces symptoms of psoriasis such as burning, itching, pain, redness and scaling.
Slovenian: Zmanjšuje tudi simptome psoriaze, na primer pekoč občutek, srbenje, bolečino, pordelost in luščenje.
English: Treatment with risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.
Slovenian: Zdravljenja z risankizumabom se ne sme začeti pri bolnikih s klinično pomembno aktivno okužbo, dokler okužba ni obravnavana ali ustrezno zdravljena.
English: It may contain a few translucent to white product-related particles.
Slovenian: Vsebuje lahko nekaj prosojnih do belih z zdravilom povezanih delcev.
English: Table 4: Efficacy and quality of life results at week 16 in adults with plaque psoriasis in IMMVENT
Slovenian: Preglednica 4: Rezultati učinkovitosti in kakovosti življenja v 16. tednu pri odraslih s psoriazo v plakih v študiji IMMVENT
English: Co-primary endpoints No impact on health-related quality of life
Slovenian: Ni vpliva na kakovost življenja, povezano z zdravjem
English: For a full dose, two injections are needed, one after the other.
Slovenian: Za celoten odmerek sta potrebni dve injekciji, ena za drugo.
English: For a full dose, 2 injections are required, one after the other.
Slovenian: Za celoten odmerek sta potrebni 2 injekciji, ena za drugo.
English: • fungal skin infection
Slovenian: • glivična okužba kože
English: Women of childbearing potential should use an effective method of contraception during treatment and for at least 21 weeks after treatment.
Slovenian: Ženske v rodni dobi morajo med zdravljenjem in vsaj še 21 tednov po zdravljenju uporabljati učinkovito kontracepcijo.
English: Examination of age, gender, race, body weight ≤130 kg, baseline PASI score, concurrent psoriatic arthritis, previous non-biologic systemic treatment, previous biologic treatment, and previous failure of a biologic did not identify differences in response to risankizumab among these subgroups.
Slovenian: Analize starosti, spola, rase, telesne mase ≤130 kg, izhodiščne ocene PASI, sočasnega psoriatičnega artritisa, predhodnega nebiološkega sistemskega zdravljenja, predhodnega biološkega zdravljenja in predhodnega neuspeha bioloških zdravil niso pokazale razlik v odzivu na risankizumab med temi podskupinami.
English: Enrolled subjects were 18 years of age and older with plaque psoriasis who had a body surface area (BSA) involvement of ≥10%, a static Physician Global Assessment (sPGA) score of ≥3 in the overall assessment (plaque thickness/induration, erythema, and scaling) of psoriasis on a severity scale of 0 to 4, a Psoriasis Area and Severity Index (PASI) score ≥12, and who were candidates for systemic therapy or phototherapy.
Slovenian: Vključeni preiskovanci so bili stari 18 let ali več in so imeli psoriazo v plakih z zajetostjo ≥ 10 % telesne površine (BSA - Body Surface Area), statično zdravnikovo globalno oceno (sPGA - static Physician Global Assessment) ≥ 3 v celokupni oceni psoriaze (debelina/induracija plakov, eritem in luščenje) na lestvici izrazitosti od 0 do 4, oceno PASI (Psoriasis Area and Severity Index) ≥ 12 in so bili kandidati za sistemsko zdravljenje ali fototerapijo.
English: Throw away used syringes in a special disposal container.
Slovenian: Porabljeni injekcijski brizgi odvrzite v poseben vsebnik za odlaganje.
English: Nonclinical data revealed no special hazard for humans based on repeat-dose toxicity studies including safety pharmacology evaluations, and a reproductive and developmental toxicity study in cynomolgus monkeys at doses of up to 50 mg/kg/week (producing exposures of about 70 times the clinical exposure at maximum recommended human dose [MRHD]).
Slovenian: Predklinični podatki niso pokazali posebne ogroženosti pri človeku na podlagi študij toksičnosti ponavljajočih se odmerkov, vključno z varnostnimi farmakološkimi ocenami, ter študije reproduktivne in razvojne toksičnosti pri opicah cynomolgus v odmerkih do 50 mg/kg/teden (ki povzročijo približno 70-kratno klinično izpostavljenost ob največjem priporočenem odmerku za človeka).
English: Please read all of section 7 before using Skyrizi
Slovenian: Prosimo vas, da v celoti preberete poglavje 7, preden začnete uporabljati zdravilo Skyrizi.
English: Patients treated with risankizumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur.
Slovenian: Bolnikom, ki se zdravijo z risankizumabom je treba naročiti, naj poiščejo zdravniško pomoč, če se jim pojavijo znaki ali simptomi klinično pomembnih kroničnih ali akutnih okužb.
English: What Skyrizi is and what it is used for
Slovenian: Kaj je zdravilo Skyrizi in za kaj ga uporabljamo
English: If a serious hypersensivity reaction occurs, administration of risankizumab should be discontinued immediately and appropriate therapy initiated.
Slovenian: Če se pojavi resna preobčutljivostna reakcija, je treba uporabo risankizumaba nemudoma prekiniti in uvesti ustrezno zdravljenje.
English: • 2 pre-filled syringes and 2 alcohol pads (included in the carton)
Slovenian: • 2 napolnjeni injekcijski brizgi in 2 alkoholna zloženca (priložena v škatli)
English: The results for the co-primary and other endpoints are presented in Table 2 and Figure 1.
Slovenian: Rezultati soprimarnega in drugih opazovanih dogodkov so prikazani v preglednici 2 in na sliki 1.
English: In 270 patients who switched from adalimumab to risankizumab without a washout period, the safety profile of risankizumab was similar to that in patients who initiated risankizumab after wash out of any prior systemic therapies.
Slovenian: Pri 270 bolnikih, ki so prešli z adalimumaba na risankizumab brez obdobja izpiranja, so bile varnostne značilnosti risankizumaba podobne kot pri bolnikih, ki so začeli zdravljenje z risankizumabom po obdobju izpiranja katerega koli predhodnega sistemskega zdravljenja.
English: What you need to know before you use Skyrizi 3.
Slovenian: Kaj morate vedeti, preden boste uporabili zdravilo Skyrizi 3.
English: For each dose, the injections should be administered at different anatomic locations (such as thighs or abdomen), and not into areas where the skin is tender, bruised, erythematous, indurated or affected by psoriasis.
Slovenian: Za vsak odmerek je treba injekciji dati na drugem anatomskem mestu (npr. na stegnu ali na trebuhu); injicirati se ne sme v predele kože, ki je občutljiva, podpluta, eritematozna, zatrdela ali prizadeta zaradi psoriaze.
English: Mutagenicity and carcinogenicity studies have not been conducted with risankizumab.
Slovenian: Študij mutagenosti in karcinogenosti z risankizumabom niso izvedli.
English: • severe itching of the skin, with a red rash or raised bumps
Slovenian: • hudo srbenje kože z rdečim izpuščajem ali dvignjenimi bulicami.
English: IMMVENT enrolled 605 subjects (301 randomised to risankizumab and 304 to adalimumab).
Slovenian: Študija IMMVENT je zajela 605 preiskovancev (301 randomiziranega na risankizumab in 304 na adalimumab).
English: • Keep Skyrizi in the original carton to protect the medicine from light until it is time to use it
Slovenian: • Shranjujte zdravilo Skyrizi v originalni škatli za zagotovitev zaščite pred svetlobo, dokler ni čas za njegovo uporabo.
English: Upper respiratory infections
Slovenian: Okužbe zgornjih dihal
English: If you have used more Skyrizi than you should or the dose has been given sooner than prescribed, talk to your doctor.
Slovenian: Če ste uporabili večji odmerek zdravila Skyrizi, kot bi smeli Če ste uporabili večji odmerek zdravila Skyrizi, kot bi smeli, ali če ste odmerek uporabili prej, kot je predpisano, se posvetujte z zdravnikom.
English: Tell your doctor, pharmacist or nurse:
Slovenian: Obvestite zdravnika, farmacevta ali medicinsko sestro:
English: The effect of risankizumab on human fertility has not been evaluated.
Slovenian: Vpliva risankizumaba na plodnost pri človeku niso ocenili.
English: The injection site reactions were all mild to moderate in severity, none were serious, and none led to discontinuation of risankizumab.
Slovenian: Vse reakcije na mestu injiciranja so bile blage do zmerne, resnih ni bilo, in niso povzročile prenehanja uporabe risankizumaba.
English: Nail Psoriasis Severity Index (NAPSI), Palmoplantar Psoriasis Severity Index (PPASI), Psoriasis Scalp Severity Index (PSSI), and Standard Error (SE) ** P < 0.01 comparing to risankizumab *** P < 0.001 comparing to risankizumab
Slovenian: Indeks jakosti psoriaze nohtov (Nail Psoriasis Severity Index, NAPSI), indeks jakosti palmoplantarne psoriaze (Psoriasis Palmoplantar Severity Index, PPASI), indeks jakosti psoriaze lasišča (Psoriasis Scalp Severity Index, PSSI) in Standardna Napaka (SN) ** P < 0,01 v primerjavi z risankizumabom *** P < 0,001 v primerjavi z risankizumabom
English: The exposure of caffeine (CYP1A2 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), metoprolol (CYP2D6 substrate) and midazolam (CYP3A substrate) following risankizumab treatment were comparable to their exposures prior to risankizumab treatment, indicating no clinically meaningful drug interactions through these enzymes.
Slovenian: Izpostavljenost kofeinu (substratu CYP1A2), varfarinu (substratu CYP2C9), omeprazolu (substratu CYP2C19), metoprololu (substratu CYP2D6) in midazolamu (substratu CYP3A) po zdravljenju z risankizumabom je bila primerljiva z izpostavljenostjo pred zdravljenjem z risankizumabom; to kaže, da ni klinično pomembnih medsebojnih delovanj zdravil preko teh encimov.
English: ULTIMMA-1 and ULTIMMA-2 enrolled 997 subjects (598 randomised to risankizumab 150 mg, 199 to ustekinumab 45 mg or 90 mg [according to baseline weight], and 200 to placebo).
Slovenian: Študiji ULTIMMA-1 in ULTIMMA-2 sta zajeli 997 preiskovancev (598 randomiziranih na risankizumab 150 mg, 199 na ustekinumab 45 mg ali 90 mg [glede na izhodiščno telesno maso] in 200 na placebo).
English: • With the other hand, gently pull the needle cover straight off
Slovenian: • Z drugo roko previdno potegnite pokrovček igle naravnost dol.
English: Patients receiving risankizumab should be monitored for signs and symptoms of active TB.
Slovenian: Bolnike, ki prejemajo risankizumab, je potrebno nadzirati za znake in simptome aktivne TB.
English: Animal studies do not indicate direct or indirect harmful effects with respect to fertility.
Slovenian: Študije na živalih ne kažejo neposrednih ali posrednih škodljivih učinkov na plodnost.
English: The mean terminal elimination half-life of risankizumab ranged from 28 to 29 days in Phase 3 studies in subjects with psoriasis.
Slovenian: Povprečni terminalni eliminacijski razpolovni čas risankizumaba je v študijah 3. faze pri preiskovancih s psoriazo segal od 28 do 29 dni.
English: Change at Week 16 (SE)
Slovenian: Sprememba v 16. tednu (SN)
English: Tell your doctor or seek medical help immediately if you notice any signs of an allergic reaction while you are taking Skyrizi such as:
Slovenian: Nemudoma obvestite zdravnika ali poiščite zdravniško pomoč, če med uporabo zdravila Skyrizi opazite kakšne znake alergijske reakcije, na primer:
English: Consideration should be given to discontinuing treatment in patients who have shown no response after 16 weeks of treatment.
Slovenian: Pri bolnikih, ki se v 16 tednih ne odzovejo na zdravljenje, je treba razmisliti o prenehanju zdravljenja.
English: Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Slovenian: Zdravilo Skyrizi je indicirano za zdravljenje zmerne do hude psoriaze v plakih pri odraslih, ki so kandidati za sistemsko zdravljenje.
English: QR code to be included
Slovenian: Vstaviti je treba QR-kodo
English: Pre-filled glass syringe with a fixed needle and needle cover, assembled in an automatic needle guard.
Slovenian: Napolnjena injekcijska brizga s fiksno iglo in pokrovčkom igle, sestavljeno z avtomatičnim ščitnikom igle.
English: Overall, subjects had a median baseline PASI score of 17.8, a median BSA of 20.0%, and a median baseline DLQI score of 13.0.
Slovenian: Na splošno so imeli preiskovanci mediano izhodiščno oceno PASI 17,8, mediano prizadetost telesne površine 20,0 % in mediano izhodiščno oceno DLQI 13,0.
English: Risankizumab may increase the risk of infection.
Slovenian: Risankizumab lahko poveča tveganje za okužbo.
English: If you are a woman who can become pregnant, you should use contraception while using this medicine and for at least 21 weeks after your last dose of Skyrizi.
Slovenian: Če ste ženska, ki lahko zanosi, morate med uporabo zdravila Skyrizi in vsaj še 21 tednov po zadnjem odmerku tega zdravila uporabljati kontracepcijsko zaščito.
English: For a more comfortable injection: Take the carton out of the refrigerator and leave it at room temperature, out of direct sunlight, for 15 to 30 minutes before injecting.
Slovenian: Da injiciranje ne bo neprijetno: Vzemite škatlo iz hladilnika in jo za 15 do 30 minut pred injiciranjem pustite na sobni temperaturi zaščiteno pred neposredno sončno svetlobo.
English: Important information to know before you inject Skyrizi
Slovenian: Pomembne informacije, s katerimi morate biti seznanjeni, preden injicirate zdravilo Skyrizi
English: • Mark the dates on your calendar so you know when to inject Skyrizi
Slovenian: • Na koledarju označite datume, tako da boste vedeli, kdaj naslednjič uporabiti zdravilo Skyrizi.
English: Fatigue Injection site reactions
Slovenian: Utrujenost Reakcije na mestu injiciranja
English: • PASI 50 to <PASI 90 were re-randomised to either continue adalimumab or switch to risankizumab
Slovenian: • PASI 50 do < PASI 90 so bili ponovno randomizirani bodisi na nadaljevanje adalimumaba ali na prehod na risankizumab,
English: • Hold the syringe in one hand
Slovenian: • Primite injekcijsko brizgo z eno roko.
English: Drug interactions between risankizumab and inhibitors, inducers, or substrates of drug metabolising enzymes are not expected and no dose adjustment is needed (see section 5.2).
Slovenian: Prav tako ni pričakovati medsebojnih delovanj med risankizumabom in zaviralci, induktorji ali substrati encimov, ki presnavljajo zdravila, tako da prilagoditev odmerka ni potrebna (glejte poglavje 5.2).
English: There is limited safety information in subjects aged ≥65 years.
Slovenian: Podatki o varnosti pri preiskovancih, starih ≥ 65 let, so omejeni.
English: IMMHANCE enrolled 507 subjects (407 randomised to risankizumab 150 mg and 100 to placebo).
Slovenian: Študija IMMHANCE je zajela 507 preiskovancev (407 randomiziranih na risankizumab 150 mg in 100 na placebo).
English: Reductions in epidermal thickness, infiltration of inflammatory cells, and expression of psoriatic disease markers were also observed in psoriatic lesions.
Slovenian: Na psoriatičnih lezijah so opažali tudi zmanjšanje debeline epidermisa, infiltracije z vnetnimi celicami in izraženosti označevalcev psoriatične bolezni.
English: Starting at week 16, subjects who were receiving adalimumab continued or switched treatment based on response:
Slovenian: Preiskovanci, ki so prejemali adalimumab, so od 16. tedna naprej zdravljenje nadaljevali ali ga zamenjali glede na odziv:
English: Do not rub the skin where you have injected.
Slovenian: Ne drgnite kože na mestu injiciranja.
English: In a 26-week chronic toxicology study in cynomolgus monkeys at doses of up to 50 mg/kg/week (about 70 times the clinical exposure at the MRHD), there were no pre-neoplastic or neoplastic lesions observed and no adverse immunotoxicity or cardiovascular effects were noted .
Slovenian: V 26-tedenski kronični toksikološki študiji pri opicah cynomolgus v odmerkih do 50 mg/kg/teden (približno 70-kratna klinična izpostavljenost ob največjem priporočenem odmerku za človeka) niso opažali predneoplastičnih ali neoplastičnih sprememb in nobenih neželenih imunotoksičnih ali srčno-žilnih učinkov.
English: Subjects randomised to adalimumab received 80 mg at week 0, 40 mg at week 1 and 40 mg every other week through week 15.
Slovenian: Preiskovanci, randomizirani na adalimumab, so dobili 80 mg 0. teden, 40 mg 1. teden in nato po 40 mg vsak drugi teden do 15. tedna.
English: Name and address of the manufacturer(s) of the biological active substance(s)
Slovenian: Ime in naslov proizvajalca (proizvajalcev) biološke učinkovine
English: Press a cotton ball or gauze pad where you have injected and hold for 10 seconds.
Slovenian: S kosmom vate ali zložencem gaze 10 sekund pritiskajte na mesto, kamor ste injicirali.
English: • Wait to remove the needle cover until just before the injection
Slovenian: • Pokrovček igle odstranite šele tik pred injiciranjem.
English: If you stop using Skyrizi
Slovenian: Če ste prenehali uporabljati zdravilo Skyrizi
English: Patients may self-inject Skyrizi after training in subcutaneous injection technique.
Slovenian: Bolniki si smejo zdravilo Skyrizi injicirati sami, potem ko se usposobijo za postopek subkutanega injiciranja.
English: Population pharmacokinetic analyses indicated that risankizumab exposure was not impacted by concomitant medications (metformin, atorvastatin, lisinopril, amlodipine, ibuprofen, acetylsalicylate and levothyroxine) used by some subjects with plaque psoriasis during the clinical studies.
Slovenian: Populacijske farmakokinetične analize so pokazale, da na izpostavljenost risankizumaba niso vplivala sočasno uporabljena zdravila (metformin, atorvastatin, lizinopril, amlodipin, ibuprofen, acetilsalicilat in levotiroksin), ki so jih v kliničnih študijah uporabljali nekateri preiskovanci s psoriazo v plakih.
English: Subjects who were originally on risankizumab and had a sPGA response of clear or almost clear at week 28 were rerandomised to continue risankizumab every 12 weeks or have treatment withdrawn.
Slovenian: Preiskovance, ki so prvotno prejemali risankizumab in so imeli v 28. tednu odziv sPGA čisto ali skoraj čisto, so ponovno randomizirali na nadaljevanje zdravljenja z risankizumabom na 12 tednov ali na prenehanje tega zdravljenja.